[alk阳性非小细胞肺癌新辅助靶向治疗进展]。

Q4 Medicine

中国肺癌杂志 Pub Date : 2024-11-20 DOI:10.3779/j.issn.1009-3419.2024.106.30

Weizhen Sun, Yuheng Zhou, Yaobin Lin, Shoucheng Feng, Hao Long

{"title":"[alk阳性非小细胞肺癌新辅助靶向治疗进展]。","authors":"Weizhen Sun, Yuheng Zhou, Yaobin Lin, Shoucheng Feng, Hao Long","doi":"10.3779/j.issn.1009-3419.2024.106.30","DOIUrl":null,"url":null,"abstract":"Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death worldwide, with anaplastic lymphoma kinase (ALK) fusion mutations accounting for approximately 4%-9% of cases. In recent years, there are increasing clinical evidences suggesting that the combination of ALK inhibitors with surgical treatment holds significant potential for clinical application in resectable early and locally advanced non-small cell lung cancer (NSCLC) patients. This review aims to summarize the advances in neoadjuvant targeted therapy for ALK fusion positive NSCLC and discuss its advantages and challenges in clinical practice.\u2029.","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 11","pages":"849-854"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732383/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].\",\"authors\":\"Weizhen Sun, Yuheng Zhou, Yaobin Lin, Shoucheng Feng, Hao Long\",\"doi\":\"10.3779/j.issn.1009-3419.2024.106.30\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death worldwide, with anaplastic lymphoma kinase (ALK) fusion mutations accounting for approximately 4%-9% of cases. In recent years, there are increasing clinical evidences suggesting that the combination of ALK inhibitors with surgical treatment holds significant potential for clinical application in resectable early and locally advanced non-small cell lung cancer (NSCLC) patients. This review aims to summarize the advances in neoadjuvant targeted therapy for ALK fusion positive NSCLC and discuss its advantages and challenges in clinical practice.\\u2029.\",\"PeriodicalId\":39317,\"journal\":{\"name\":\"中国肺癌杂志\",\"volume\":\"27 11\",\"pages\":\"849-854\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732383/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国肺癌杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3779/j.issn.1009-3419.2024.106.30\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国肺癌杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3779/j.issn.1009-3419.2024.106.30","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

肺癌仍然是世界范围内最常见的癌症和癌症相关死亡的主要原因，间变性淋巴瘤激酶（ALK）融合突变约占病例的4%-9%。近年来，越来越多的临床证据表明，ALK抑制剂联合手术治疗在可切除的早期和局部晚期非小细胞肺癌（NSCLC）患者中具有重要的临床应用潜力。本文旨在总结ALK融合阳性NSCLC新辅助靶向治疗的进展，并讨论其在临床实践中的优势和挑战。 。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].

Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death worldwide, with anaplastic lymphoma kinase (ALK) fusion mutations accounting for approximately 4%-9% of cases. In recent years, there are increasing clinical evidences suggesting that the combination of ALK inhibitors with surgical treatment holds significant potential for clinical application in resectable early and locally advanced non-small cell lung cancer (NSCLC) patients. This review aims to summarize the advances in neoadjuvant targeted therapy for ALK fusion positive NSCLC and discuss its advantages and challenges in clinical practice. .

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国肺癌杂志 Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.40

自引率

0.00%

发文量

5131

审稿时长

14 weeks

期刊介绍： Chinese Journal of Lung Cancer(CJLC, pISSN 1009-3419, eISSN 1999-6187), a monthly Open Access journal, is hosted by Chinese Anti-Cancer Association, Chinese Antituberculosis Association, Tianjin Medical University General Hospital. CJLC was indexed in DOAJ, EMBASE/SCOPUS, Chemical Abstract(CA), CSA-Biological Science, HINARI, EBSCO-CINAHL,CABI Abstract, Global Health, CNKI, etc. Editor-in-Chief: Professor Qinghua ZHOU.